Abstract
Protein kinase C theta (PKC-) is a key kinase in mediating T cell receptor (TCR) signals. PKC- activated by T cell receptor (TCR) engagement translocates to immunological synapses and regulates the activation of transcriptional factors NF-κB, AP-1, and NFAT. These transcription factors then activate target genes such as IL-2. T cells deficient in PKC- display defects in T cell activation, survival, activation-induced cell death, and the differentiation into inflammatory T cells, both in vitro and in vivo. Since these effector T helper cells are responsible for mediating autoimmunity, selective inhibition of PKC- is considered a treatment for prevention of autoimmune diseases and allograft rejection.
Keywords: PKC-, T cells, TCR signaling, autoimmunity, transplantation rejection, T cell receptor, TCR, antigen presenting cells, APC, histocompatibility complex, MHC, protein tyrosine kinase, diacylglycerol, DAG, central SMAC, peripheral SMAC, distal SMAC, Activationinduced cell death, airway hyperresponsiveness, myelin oligodendrocyte glycoprotein, MOG, experimental autoimmune encephalitis, EAE, collagen-induced arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Volume: 10 Issue: 4
Author(s): Myung-Ja Kwon, Ruiqing Wang, Jian Ma and Zuoming Sun
Affiliation:
Keywords: PKC-, T cells, TCR signaling, autoimmunity, transplantation rejection, T cell receptor, TCR, antigen presenting cells, APC, histocompatibility complex, MHC, protein tyrosine kinase, diacylglycerol, DAG, central SMAC, peripheral SMAC, distal SMAC, Activationinduced cell death, airway hyperresponsiveness, myelin oligodendrocyte glycoprotein, MOG, experimental autoimmune encephalitis, EAE, collagen-induced arthritis
Abstract: Protein kinase C theta (PKC-) is a key kinase in mediating T cell receptor (TCR) signals. PKC- activated by T cell receptor (TCR) engagement translocates to immunological synapses and regulates the activation of transcriptional factors NF-κB, AP-1, and NFAT. These transcription factors then activate target genes such as IL-2. T cells deficient in PKC- display defects in T cell activation, survival, activation-induced cell death, and the differentiation into inflammatory T cells, both in vitro and in vivo. Since these effector T helper cells are responsible for mediating autoimmunity, selective inhibition of PKC- is considered a treatment for prevention of autoimmune diseases and allograft rejection.
Export Options
About this article
Cite this article as:
Kwon Myung-Ja, Wang Ruiqing, Ma Jian and Sun Zuoming, PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/1871530311006040367
DOI https://dx.doi.org/10.2174/1871530311006040367 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Current Medicinal Chemistry Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews Recognition of Peptides by Antibodies and Investigations of Affinity Using Biosensor Technology
Combinatorial Chemistry & High Throughput Screening Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry Leukocyte Function-Associated Antigen-1: Structure, Function and Application Prospects
Protein & Peptide Letters Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets Editorial: Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Autoimmunity and Apoptosis - Therapeutic Implications
Current Medicinal Chemistry The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents